• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4642682)   Today's Articles (182)   Subscriber (50542)
For: Ramalingam SS, Pérol M, Reck M, Kowalyszyn RD, Gautschi O, Kimmich M, Cho EK, Czyzewicz G, Grigorescu A, Karaseva N, Dakhil S, Lee P, Zimmerman A, Sashegyi A, Alexandris E, Carter GC, Winfree KB, Garon EB. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Clin Lung Cancer 2018;19:270-279.e3. [PMID: 29373274 DOI: 10.1016/j.cllc.2017.12.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 11/30/2017] [Accepted: 12/17/2017] [Indexed: 11/28/2022]
Number Cited by Other Article(s)
1
Ohno H, Hayashi T, Torii S, Niwa M, Katagiri N, Nakao Y, Mano S, Takimoto N, Hirashita T. Influence of Previous Therapy for Neutropenia Caused by Combination Therapy of Ramucirumab and Docetaxel. Cancers (Basel) 2024;16:2076. [PMID: 38893195 PMCID: PMC11171386 DOI: 10.3390/cancers16112076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2024] [Revised: 05/27/2024] [Accepted: 05/28/2024] [Indexed: 06/21/2024]  Open
2
Soon YY, Furnback W, Kim J, Chuang PY, Chavez G, Proescholdt C, Chee Koh CY. Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum-Based Chemotherapy Failure Setting. JTO Clin Res Rep 2023;4:100579. [PMID: 37942209 PMCID: PMC10628857 DOI: 10.1016/j.jtocrr.2023.100579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 08/23/2023] [Accepted: 09/18/2023] [Indexed: 11/10/2023]  Open
3
de Langen AJ, Johnson ML, Mazieres J, Dingemans AMC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023;401:733-746. [PMID: 36764316 DOI: 10.1016/s0140-6736(23)00221-0] [Citation(s) in RCA: 169] [Impact Index Per Article: 169.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 01/20/2023] [Accepted: 01/23/2023] [Indexed: 02/10/2023]
4
Matsumoto K, Tamiya A, Inagaki Y, Taniguchi Y, Matsuda Y, Kawachi H, Tamiya M, Tanizaki S, Uchida J, Ueno K, Yanase T, Suzuki H, Atagi S. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. J Geriatr Oncol 2022;13:207-213. [PMID: 34602370 DOI: 10.1016/j.jgo.2021.09.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 08/09/2021] [Accepted: 09/03/2021] [Indexed: 02/04/2023]
5
Chen YY, Chang SC, Chang CY, Chang CF, Lai YC, Wei YF, Chen CY. Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. BMC Cancer 2021;21:1225. [PMID: 34781919 PMCID: PMC8594240 DOI: 10.1186/s12885-021-08920-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Accepted: 10/25/2021] [Indexed: 11/22/2022]  Open
6
Zhang N, Li M, Xu X, Zhang Y, Liu Y, Zhao M, Li P, Chen J, Fukuda T, Gu J, Jin X, Li W. Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation. Eur J Immunol 2020;50:1820-1833. [PMID: 32460355 DOI: 10.1002/eji.202048543] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 04/24/2020] [Accepted: 05/25/2020] [Indexed: 12/13/2022]
7
Sakaguchi T, Furuya N, Ito K, Hida N, Morikawa K, Komase Y, Inoue T, Hataji O, Mineshita M. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer. Thorac Cancer 2020;11:1559-1565. [PMID: 32291896 PMCID: PMC7262941 DOI: 10.1111/1759-7714.13429] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 03/20/2020] [Accepted: 03/21/2020] [Indexed: 11/29/2022]  Open
8
Furuya N, Ito K, Sakaguchi T, Hida N, Kakinuma K, Morikawa K, Inoue T, Komase Y, Hataji O, Mineshita M. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. Oncology 2020;98:661-668. [PMID: 32464632 PMCID: PMC7592951 DOI: 10.1159/000507050] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Accepted: 03/05/2020] [Indexed: 01/17/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA